Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated...
Read moreLatest News
Category: ASX
Telix Announces Record-Breaking Presence at EANM 2025
Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona...
Read more
CMS Grants Transitional Pass-Through Status for Gozellix
Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide...
Read more
Telix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA
Telix today announces that it has reached agreement with the United States (U.S.) Food and Drug Administration (FDA) regarding resubmission of its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18...
Read more
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August...
Read more
Telix H1 2025 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August...
Read more
Telix Reports $204M Revenue, Up 63% YOY
Telix today provides an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). All figures are in USD unless stated...
Read more
Gozellix Receives Permanent HCPCS Code
Telix today announces that its next-generation PSMA PET imaging agent, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), has been granted a permanent Healthcare Common Procedure Coding System...
Read more
Telix’s Illuccix PSMA-PET Imaging Agent Approved in France
Telix announces its Annual General Meeting of shareholders to be held...
Read more